COVID Vaccine and Leukemia: Is There a Connection?

No established causal connection exists between COVID-19 vaccines and the development of leukemia. A handful of case reports describe leukemia diagnoses occurring shortly after vaccination, but large population studies have not shown an increased risk of blood cancers in vaccinated people. The question persists in part because of online misinformation about “turbo cancers,” and in part because the relationship between COVID vaccines and leukemia runs in the opposite direction from what many people assume: the more pressing concern is how well the vaccines work in people who already have leukemia, not whether the vaccines cause it.

What Large Studies Show About Cancer Risk After Vaccination

The strongest evidence against a vaccine-leukemia link comes from population-level data. A large Korean cohort study drew on national health insurance records covering more than 8.4 million individuals between 2021 and 2023, comparing cancer risks in vaccinated and unvaccinated groups using statistical models that adjusted for other risk factors.¹ Studies of this size carry far more weight than individual case reports because they can detect whether a pattern exists across millions of people rather than in isolated instances. When researchers look at the data this way, there is no signal that COVID vaccination increases the overall risk of developing cancer.

This matters because cancer diagnoses happen constantly in any population. With billions of vaccine doses administered worldwide, some people will inevitably be diagnosed with leukemia in the days or weeks after receiving a shot, purely by coincidence. The only way to tell whether the vaccine played a role is to compare the rate of new leukemia diagnoses in vaccinated people against the rate in unvaccinated people with similar demographics. When that comparison is done at scale, the rates do not diverge.

Case Reports and Why They Do Not Prove Causation

Several published case reports describe patients diagnosed with various forms of leukemia shortly after COVID-19 vaccination. One report documented a case of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (a specific subtype of ALL) occurring after a bivalent mRNA booster dose. The authors acknowledged that there is “currently no sufficient evidence correlating anti-spike protein immune responses and hematopoietic adverse events of vaccinations,” though they proposed that the immune response to the spike protein could theoretically act as a trigger.² Another report described a patient who developed T-cell acute lymphoblastic leukemia with an unusual cell surface profile, with enlarged lymph nodes first noticed two days after a first vaccine dose.³

These reports are worth publishing because they alert other clinicians to watch for patterns, but they cannot establish that a vaccine caused the disease. Leukemia develops over months to years through the accumulation of genetic mutations in blood-forming cells. A cancer that shows up clinically two days or even two weeks after a vaccine dose was almost certainly already growing before the shot. What the vaccine might do in rare instances is provoke an immune response vigorous enough to make a pre-existing, undetected malignancy become symptomatic sooner, essentially unmasking something that was already there rather than creating it. Even that hypothesis remains speculative.

A separate review article explored potential genetic and molecular mechanisms by which mRNA vaccination could theoretically contribute to blood cancers, drawing on existing scientific literature.⁴ Such reviews are useful for identifying areas that warrant more research, but their existence does not mean the mechanisms they describe actually occur in vaccinated people at any meaningful rate.

When Vaccine Side Effects Look Like Leukemia

One particularly instructive case involved a patient who appeared to have acute leukemia after mRNA COVID-19 vaccination. A blood smear showed a large number of immature cells, which is a hallmark of leukemia, prompting a bone marrow biopsy. The biopsy came back normal. The patient’s blood abnormalities resolved with supportive care, and the episode was ultimately diagnosed as an adverse reaction to vaccination rather than a blood cancer.⁵

This case is a useful reminder that vaccines can cause temporary disruptions in blood cell counts that superficially resemble serious blood diseases. Rare hematological side effects of COVID-19 vaccination have been documented, including transient drops in platelets and abnormal shifts in white blood cell populations.⁶ These effects are generally short-lived and self-resolving, but they can cause alarm if a routine blood test happens to fall during that window. In a person already anxious about a possible link between vaccines and blood cancer, a transiently abnormal lab result can feel like confirmation of their fears when it is actually a benign and temporary immune response.

The “Turbo Cancer” Claim

The idea that mRNA COVID-19 vaccines cause aggressive, fast-growing cancers, sometimes called “turbo cancers” in online circles, has no support from epidemiological data. The mRNA in these vaccines cannot enter a cell’s nucleus, which is where your DNA lives, so it cannot alter your genetic code. The mRNA fragments degrade rapidly after the immune system has used them to learn the spike protein’s shape, and the vaccine’s ingredients do not accumulate in the body over time.⁷

Some of the confusion stems from laboratory research that has nothing to do with COVID vaccines. Scientists have developed specialized lipid nanoparticles that can deliver RNA directly to blood-forming stem cells, a technology being explored as a potential treatment for genetic blood disorders like sickle cell disease.⁸ These experimental nanoparticles are specifically engineered with antibodies that target a receptor (CD117) found on stem cells, allowing them to home in on those cells with high precision.⁹ COVID vaccine nanoparticles are not designed this way. They lack the targeting antibodies needed to seek out stem cells, and the lipid nanoparticles in vaccines are a fundamentally different formulation from the engineered research tools used in gene therapy experiments. Conflating the two is like saying a city bus and a Formula 1 car are the same thing because they both have engines.

A small metabolomic study compared bone marrow samples from vaccinated leukemia patients, unvaccinated leukemia patients, and healthy controls. The metabolic profiles of vaccinated leukemia patients were more similar to those of unvaccinated leukemia patients than to healthy people, suggesting that the leukemia itself, not the vaccine, was the primary driver of metabolic differences. The researchers concluded that their findings do not support a causal link between mRNA vaccination and leukemia development.¹⁰

The Real Concern Runs in the Other Direction

For people with leukemia, the far more pressing issue is not whether the vaccine causes their disease but whether it protects them from COVID-19 well enough. Leukemia and its treatments can suppress the immune system, which means the body may not mount a strong enough response to vaccination to build adequate protection. This is where the evidence gets genuinely complicated.

In a study of 44 patients with chronic lymphocytic leukemia (CLL), only about half produced detectable antibodies against SARS-CoV-2 after vaccination. Patients who had never received CLL treatment fared much better, with 94% developing antibodies, compared to just 23% of those on active therapy.¹¹ A systematic review and meta-analysis that compiled data from multiple studies found that only about 51% to 75% of CLL patients achieved an adequate antibody response after COVID vaccination, substantially lower than the general population.¹²

The consequences of this weakened immune response are real. Data from a multinational registry covering 41 centers in 10 countries tracked 143 patients with blood cancers who developed COVID-19 despite being fully vaccinated. The overall mortality rate among these patients was about 13%, and those with no or low antibody response to the vaccine died at dramatically higher rates: roughly 29% compared to about 2% among those who had produced antibodies.¹³ Older age and lack of antibody response were independently associated with death.

How Different Leukemia Types and Treatments Affect Vaccine Response

Not all blood cancers impair vaccine response equally. Patients with acute myeloid leukemia (AML) tended to respond to vaccination about as well as healthy individuals, while those with myelodysplastic syndromes (MDS) initially showed a weaker response that improved significantly with a third dose, even in patients receiving active treatment.¹⁴ This pattern held in a separate cohort of myeloid neoplasm patients who were evaluated for neutralizing antibodies against the original virus strain and multiple variants after second and third vaccine doses.¹⁵

The specific drugs a patient is taking matter enormously. In CLL, treatments that target a protein called BTK (like ibrutinib) or that deplete B cells (like rituximab) dramatically reduce the odds of building antibodies after vaccination. In one study, none of the patients receiving a combination of venetoclax and a recent anti-CD20 antibody produced detectable antibodies.¹¹ Two CLL patients in a safety study developed autoimmune hemolytic anemia after vaccination, a known complication in CLL that the vaccine may have triggered in the context of already-progressive disease. Both recovered with treatment.¹⁶

For patients who have undergone stem cell transplant or CAR-T cell therapy, the picture is different still. Transplant recipients showed increasing antibody levels with vaccination regardless of when they started their vaccine series, but CAR-T cell recipients who began vaccination within four months of treatment showed essentially no improvement in antibody levels.¹⁷ This makes sense biologically: CAR-T therapy deliberately destroys B cells, which are the cells responsible for making antibodies. Encouragingly, even patients who cannot make antibodies because of CAR-T-related B cell depletion can still mount a robust T-cell response to the vaccine, providing at least some layer of immune protection.¹⁸ Receiving four or more total vaccine doses significantly improved seroconversion in CAR-T recipients compared to those who received only two doses.¹⁹

Vaccination in Children With Leukemia

Childhood acute lymphoblastic leukemia is one of the most common childhood cancers, so the question of whether these children can safely receive COVID vaccines and benefit from them is clinically significant. The evidence is reassuring on both fronts. In a study of 20 vaccinated children and young adults undergoing ALL chemotherapy, 80% developed detectable spike-reactive antibodies or T cells, and most of those T-cell responses were multifunctional, meaning they produced multiple types of immune signals. Immune responses were observed even among patients who were lymphopenic or on intensive chemotherapy.²⁰

A phase 1/2 trial in children with acute leukemia found that the vaccine was well tolerated. The antibody response was initially weaker in patients than in their healthy siblings (about 52% versus 100% after the first dose), but T-cell responses were similar between the two groups. A third dose boosted antibody levels further, and both types of immune response lasted at least a year. No severe COVID-19 occurred in any participant during the study.²¹ A separate investigation of 259 pediatric participants, including children with ALL, found that while antigen-specific antibody responses were somewhat dampened in the leukemia group, neutralizing antibody levels were comparable to or even higher than those in healthy children for several viral variants.²²

How Clinicians Time Vaccination Around Leukemia Treatment

Guidelines from major oncology organizations, including the American Society of Clinical Oncology, recommend that vaccination should be considered a core part of cancer care, not an optional add-on. This includes documenting a patient’s vaccine status at the first visit, providing recommended vaccines in a timely way, and revaccinating after treatments like stem cell transplant, CAR-T therapy, or B-cell-depleting drugs that effectively reset the immune system.²³

The timing of vaccination relative to treatment matters. General guidance suggests giving the vaccine before starting chemotherapy when possible, or between treatment cycles and away from the point when blood counts are at their lowest. For other cancer therapies, vaccination is best timed for a period when blood counts show signs of recovery. Cancer treatment for newly diagnosed patients should not be delayed for the sake of getting vaccinated first.²⁴

Additional vaccine doses appear to help. Among patients with blood cancers who received a fourth dose, about 77% had positive antibodies afterward, and that figure rose to roughly 91% after a fifth dose. Among those who were antibody-negative before their fourth dose, about a third converted to positive afterward.²⁵ This pattern of incremental benefit with repeated dosing is one reason oncologists generally encourage their patients with blood cancers to stay up to date with boosters even when the early doses did not produce a measurable antibody response.

Why COVID Itself Poses a Greater Threat Than the Vaccine

For people with leukemia or a history of blood cancer treatment, COVID-19 infection itself carries risks that dwarf any theoretical concern about the vaccine. The multinational registry data showing 13% mortality in fully vaccinated blood cancer patients who caught COVID illustrates the stakes: even with vaccination, these patients face meaningful danger from the virus itself.¹³ Among long-term survivors of bone marrow transplant, the risk of catching COVID was similar to that of the general population, but behaviors like consistent mask-wearing in public cut the hazard roughly in half.²⁶

The concern about a vaccine-leukemia connection is understandable, given how frightening a cancer diagnosis is and how natural it is to search for a cause. But the current evidence consistently points in one direction: vaccination does not cause leukemia, and for people living with the disease, it remains one of the more important tools for staying alive through a pandemic. The immune response may be imperfect, the timing may need to be carefully managed around treatment, and extra doses may be necessary, but the benefit of whatever protection the vaccine can provide outweighs the speculative risk of a connection that population data have not borne out.